Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.
A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.
Presentations of phase III data at the American Society of Clinical Oncology annual meeting in Chicago further support the conclusion that the oral androgen receptor inhibitor enzalutamide (XTANDI) addresses an unmet therapeutic need for metastatic castration-resistant prostate cancer in the pre-chemotherapy setting.
Patients with interstitial cystitis/bladder pain syndrome who have low bladder capacity have a significantly different gene expression profile than both IC/BPS patients with normal bladder capacity and those without the condition, researchers reported in a recently published pilot study.
Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.